• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: Follistatin291-IgG2 Fc fusion protein
Date Designated: 07/03/2018
Orphan Designation: Treatment of facioscapulohumeral muscular dystrophy
Orphan Designation Status: Designated/Designation Withdrawn or Revoked
Date Designation Withdrawn or Revoked: 10/04/2019
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, Massachusetts 02139
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.